Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 2
  5. Article
Volume 23, Issue 2
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Objectives

Growing evidence suggests that repeated-dose intravenous ketamine in patients with depression had rapid antianhedonic effects. However, a comparison of the antianhedonic effects of repeated-dose intravenous ketamine between younger adults and older depressed patients has not been examined.

Methods

To the best of my knowledge, this study with a total of 135 patients with major depressive episodes (MDE) is the first to compare the antianhedonic effects between younger adult (n = 116) and older (n = 19) depressed patients receiving six ketamine infusions (0.5 mg/kg over 40 min). Montgomery-Åsberg Depression Rating Scale (MADRS) was applied in this study to evaluate the clinical symptoms, and MADRS anhedonia item scoring was used to evaluate anhedonia symptoms.

Results

Patients received six open-label intravenous infusions of ketamine for 12 days. MADRS anhedonia subscale scores decreased in both younger (3.3, 95% CI = 2.5-4.1, 0.05) and older (2.8, 95% CI = 1.1-4.6, 0.05) MDE patients at 4h after the first infusion compared to baseline scores and the reduction was maintained over the subsequent infusion period in both groups (all < 0.05). Younger MDE patients had lower MADRS anhedonia subscale scores on day 26 compared with older patients ( = 0.02). Compared with younger adult MDE patients, older patients had a lower antianhedonic response (51.7% [95% CI = 42.5%-61.0%] 31.6% [95% CI = 8.6%-54.6%)] and remission (24.1% [95% CI = 16.2%-32.0%] 0%).

Conclusion

This study indicates that repeated-dose intravenous ketamine administration induces rapid and robust antianhedonic effects in older MDE patients. However, older MDE patients displayed less response to ketamine than younger adult MDE patients.

Registration Number

ChicCTR-OOC-17012239.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X23666240923112548
2024-09-23
2024-12-26

  • From This Site

    /content/journals/cn/10.2174/1570159X23666240923112548
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. World Health OrganizationMental health and older adults.Available from: http://www.who.int/mediacentre/factsheets/fs381/en/ 2016
     [Google Scholar]
  2. AlexopoulosG.S. Mechanisms and treatment of late-life depression.Transl. Psychiatry20199118810.1038/s41398‑019‑0514‑6 31383842
     [Google Scholar]
  3. HallC.A. Reynolds-IIIC.F. Late-life depression in the primary care setting: Challenges, collaborative care, and prevention.Maturitas201479214715210.1016/j.maturitas.2014.05.026 24996484
     [Google Scholar]
  4. DillonC. AllegriR.F. SerranoC.M. IturryM. SalgadoP. GlaserF.B. TaraganoF.E. Late- versus early-onset geriatric depression in a memory research center.Neuropsychiatr. Dis. Treat.2009551752610.2147/NDT.S7320 19851519
     [Google Scholar]
  5. AzizR. SteffensD.C. What are the causes of late-life depression?Psychiatr. Clin. North Am.201336449751610.1016/j.psc.2013.08.001 24229653
     [Google Scholar]
  6. DongM. ZhuX.M. ZhengW. LiX.H. NgC.H. UngvariG.S. XiangY.T. Electroconvulsive therapy for older adult patients with major depressive disorder: A systematic review of randomized controlled trials.Psychogeriatrics201818646847510.1111/psyg.12359 30073725
     [Google Scholar]
  7. KokR.M. ReynoldsC.F.III Management of depression in older adults: a review.JAMA2017317202114212210.1001/jama.2017.5706 28535241
     [Google Scholar]
  8. SalzmanC. WongE. WrightB.C. Drug and ECT treatment of depression in the elderly, 1996-2001: A literature review.Biol. Psychiatry200252326528410.1016/S0006‑3223(02)01337‑9 12182932
     [Google Scholar]
  9. GrigoriadisS. KennedyS.H. BagbyR.M. A comparison of antidepressant response in younger and older women.J. Clin. Psychopharmacol.200323440540710.1097/01.jcp.0000085415.08426.c6 12920418
     [Google Scholar]
  10. KatonaC.L.E. Psychotropics and drug interactions in the elderly patient.Int. J. Geriatr. Psychiatry200116S1Suppl. 1S86S9010.1002/1099‑1166(200112)16:1+<:AID‑GPS564>3.0.CO;2‑Y 11748792
     [Google Scholar]
  11. GildengersA.G. HouckP.R. MulsantB.H. PollockB.G. MazumdarS. MillerM.D. DewM.A. FrankE. KupferD.J. ReynoldsC.F.III Course and rate of antidepressant response in the very old.J. Affect. Disord.2002691-317718410.1016/S0165‑0327(01)00334‑2 12103464
     [Google Scholar]
  12. KatonaC. Managing depression and anxiety in the elderly patient.Eur. Neuropsychopharmacol.200010Suppl. 4S427S43210.1016/S0924‑977X(00)00109‑7 11114487
     [Google Scholar]
  13. MoultonC.D. StrawbridgeR. TsapekosD. OpreaE. CarterB. HayesC. CleareA.J. MarwoodL. MantinghT. YoungA.H. The Maudsley 3-item Visual Analogue Scale (M3VAS): Validation of a scale measuring core symptoms of depression.J. Affect. Disord.202128228028310.1016/j.jad.2020.12.185 33418379
     [Google Scholar]
  14. WinerE.S. JordanD.G. CollinsA.C. Conceptualizing anhedonias and implications for depression treatments.Psychol. Res. Behav. Manag.20191232533510.2147/PRBM.S159260 31191054
     [Google Scholar]
  15. ZhengW. CenQ. NieS. LiM. ZengR. ZhouS. CaiD. JiangM. HuangX. Serum BDNF levels and the antidepressant effects of electroconvulsive therapy with ketamine anaesthesia: a preliminary study.PeerJ20219e1069910.7717/peerj.10699 33604173
     [Google Scholar]
  16. PelizzaL. FerrariA. Anhedonia in schizophrenia and major depression: state or trait?Ann. Gen. Psychiatry2009812210.1186/1744‑859X‑8‑22 19811665
     [Google Scholar]
  17. WuthrichV.M. JohncoC.J. WetherellJ.L. Differences in anxiety and depression symptoms: Comparison between older and younger clinical samples.Int. Psychogeriatr.20152791523153210.1017/S1041610215000526 25892278
     [Google Scholar]
  18. Di GiannantonioM. Di IorioG. GuglielmoR. De BerardisD. ContiC.M. AcciavattiT. CornelioM. MartinottiG. Major depressive disorder, anhedonia and agomelatine: An open-label study.J. Biol. Regul. Homeost. Agents2011251109114 21382280
     [Google Scholar]
  19. BoyerP. TassinJ.P. FalissartB. TroyS. Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression.J. Clin. Pharm. Ther.200025536337110.1046/j.1365‑2710.2000.00302.x 11123488
     [Google Scholar]
  20. SpanoM.C. LorussoM. PettorrusoM. ZorattoF. Di GiudaD. MartinottiG. GiannantonioM. Anhedonia across borders: Transdiagnostic relevance of reward dysfunction for noninvasive brain stimulation endophenotypes.CNS Neurosci. Ther.201925111229123610.1111/cns.13230 31638332
     [Google Scholar]
  21. LallyN. NugentA.C. LuckenbaughD.A. AmeliR. RoiserJ.P. ZarateC.A. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.Transl. Psychiatry2014410e46910.1038/tp.2014.105 25313512
     [Google Scholar]
  22. LallyN. NugentA.C. LuckenbaughD.A. NiciuM.J. RoiserJ.P. ZarateC.A.Jr Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.J. Psychopharmacol.201529559660710.1177/0269881114568041 25691504
     [Google Scholar]
  23. ZhengW. GuL.M. SunC.H. ZhouY.L. WangC.Y. LanX.F. ZhangB. NingY.P. Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.J. Affect. Disord.202230010911310.1016/j.jad.2021.12.105 34965393
     [Google Scholar]
  24. DelfinoR.S. Del-PortoJ.A. SurjanJ. MagalhãesE. SantL.C.D. LuccheseA.C. TuenaM.A. NakahiraC. FavaV.A.R. SteglichM.S. BarbosaM.G. SarinL.M. LacerdaA.L.T. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression.J. Affect. Disord.202127851551810.1016/j.jad.2020.09.056 33017679
     [Google Scholar]
  25. MontgomeryS.A. ÅsbergM. A new depression scale designed to be sensitive to change.Br. J. Psychiatry1979134438238910.1192/bjp.134.4.382 444788
     [Google Scholar]
  26. ZhongB.L. WangY. ChenH.H. WangX.H. Reliability, validity and sensitivity of Montgomery-Åsberg Depression Rating Scale for patients with current major depressive disorder.Chinese J. Behav. Med. Brain Sci.20112018587[in Chinese].
     [Google Scholar]
  27. PennybakerS. RoachB.J. FryerS.L. BadathalaA. WallaceA.W. MathalonD.H. MartonT.F. Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression.Psychopharmacology (Berl.)2021238113229323710.1007/s00213‑021‑05939‑z 34363507
     [Google Scholar]
  28. ZhengW. ZhouY.L. LiuW.J. WangC.Y. ZhanY.N. LiH.Q. ChenL.J. LiM.D. NingY.P. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.J. Psychiatr. Res.2018106616810.1016/j.jpsychires.2018.09.013 30278319
     [Google Scholar]
  29. ZhanY. ZhangB. ZhouY. ZhengW. LiuW. WangC. LiH. ChenL. YuL. WalterM. LiM. LiM.D. NingY. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.J. Affect. Disord.201925120521210.1016/j.jad.2019.03.071 30927581
     [Google Scholar]
  30. ZhengW. ZhouY.L. LiuW.J. WangC.Y. ZhanY.N. LiH.Q. ChenL.J. LiM.D. NingY.P. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder.J. Psychopharmacol.201933449450110.1177/0269881119827811 30789302
     [Google Scholar]
  31. HamiltonM. A rating scale for depression.J. Neurol. Neurosurg. Psychiatry1960231566210.1136/jnnp.23.1.56 14399272
     [Google Scholar]
  32. C F KuokK. LiL. XiangY.T. NogueiraB.O.C.L. UngvariG.S. NgC.H. ChiuH.F.K. TranL. MengL.R. Quality of life and clinical correlates in older adults living in the community and in nursing homes in Macao.Psychogeriatrics201717319419910.1111/psyg.12214 28093847
     [Google Scholar]
  33. ZhengW. LuoX.N. LiH.Y. KeX.Y. DaiQ. ZhangC.J. NgC.H. UngvariG.S. XiangY.T. NingY.P. Prevalence of insomnia symptoms and their associated factors in patients treated in outpatient clinics of four general hospitals in Guangzhou, China.BMC Psychiatry201818123210.1186/s12888‑018‑1808‑6 30021544
     [Google Scholar]
  34. CaoB. ParkC. SubramaniapillaiM. LeeY. IacobucciM. MansurR.B. ZuckermanH. PhanL. McIntyreR.S. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder.Front. Psychiatry2019101710.3389/fpsyt.2019.00017 30766492
     [Google Scholar]
  35. ZhengW. GuL.M. ZhouY.L. WangC.Y. LanX.F. ZhangB. ShiH.S. WangD.F. NingY.P. Association of VEGF with antianhedonic effects of repeated-dose intravenous ketamine in treatment-refractory depression.Front. Psychiatry20211278097510.3389/fpsyt.2021.780975 34925104
     [Google Scholar]
  36. ShiromaP.R. JohnsB. KuskowskiM. WelsJ. ThurasP. AlbottC.S. LimK.O. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.J. Affect. Disord.201415512312910.1016/j.jad.2013.10.036 24268616
     [Google Scholar]
  37. aan het RotM. CollinsK.A. MurroughJ.W. PerezA.M. ReichD.L. CharneyD.S. MathewS.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.Biol. Psychiatry201067213914510.1016/j.biopsych.2009.08.038 19897179
     [Google Scholar]
  38. ZanardiR. CusinC. RossiniD. De RonchiD. SerrettiA. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression.J. Clin. Psychopharmacol.200323653553910.1097/01.jcp.0000095344.32154.d3 14624182
     [Google Scholar]
  39. ZhengW. ZhouY.L. WangC.Y. LanX.F. NingY.P. A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.J. Affect. Disord.202333414515110.1016/j.jad.2023.04.120 37160235
     [Google Scholar]
  40. SinghI. MorganC. CurranV. NuttD. SchlagA. McShaneR. Ketamine treatment for depression: Opportunities for clinical innovation and ethical foresight.Lancet Psychiatry20174541942610.1016/S2215‑0366(17)30102‑5 28395988
     [Google Scholar]
  41. XiongJ. LipsitzO. Chen-LiD. RosenblatJ.D. RodriguesN.B. CarvalhoI. LuiL.M.W. GillH. NarsiF. MansurR.B. LeeY. McIntyreR.S. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.J. Psychiatr. Res.2021134576810.1016/j.jpsychires.2020.12.038 33360864
     [Google Scholar]
  42. MartinottiG. Dell’OssoB. Di LorenzoG. MainaG. BertolinoA. ClericiM. BarlatiS. RossoG. Di NicolaM. MarcatiliM. d’AndreaG. CavallottoC. ChiappiniS. De FilippisS. NicolòG. De FazioP. AndriolaI. ZanardiR. NuciforaD. Di MauroS. BassettiR. PettorrusoM. McIntyreR.S. SensiS.L. di GiannantonioM. VitaA. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar TREATMENT‐RESISTANT depression.Bipolar Disord.202325323324410.1111/bdi.13296 36636839
     [Google Scholar]
  43. d’AndreaG. PettorrusoM. LorenzoG.D. MancusiG. McIntyreR.S. MartinottiG. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?Eur. Neuropsychopharmacol.202370495510.1016/j.euroneuro.2023.02.010 36867895
     [Google Scholar]
  44. ZhengW. GuL. ZhouY. WangC. LanX. ZhangB. LiZ. NingY. Baseline blasma BDNF levels are associated with antianhedonic effects of repeated-dose intravenous ketamine in major depressive disorder.Curr. Neuropharmacol.202321410131021 36173064
     [Google Scholar]
  45. Ochs-RossR. DalyE.J. ZhangY. LaneR. LimP. MorrisonR.L. HoughD. ManjiH. DrevetsW.C. SanacoraG. SteffensD.C. AdlerC. McShaneR. GaillardR. WilkinsonS.T. SinghJ.B. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.Am. J. Geriatr. Psychiatry202028212114110.1016/j.jagp.2019.10.008 31734084
     [Google Scholar]
  46. GeorgeD. GálvezV. MartinD. KumarD. LeydenJ. Hadzi-PavlovicD. HarperS. BrodatyH. GlueP. TaylorR. MitchellP.B. LooC.K. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression.Am. J. Geriatr. Psychiatry201725111199120910.1016/j.jagp.2017.06.007 28739263
     [Google Scholar]
  47. LijffijtM. MurphyN. IqbalS. GreenC.E. IqbalT. ChangL.C. HaileC.N. HirschL.C. RamakrishnanN. FallD.A. SwannA.C. Al JurdiR.K. MathewS.J. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: A Bayesian adaptive randomization trial.Neuropsychopharmacology202247510881095 34839364
     [Google Scholar]
  48. MashourG.A. Ben AbdallahA. PryorK.O. El-GabalawyR. VlisidesP.E. JacobsohnE. LenzeE. MaybrierH.R. VeselisR.A. AvidanM.S. Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.Br. J. Anaesth.201812151075108310.1016/j.bja.2018.03.030 30336852
     [Google Scholar]
  49. SørensenM.J. NissenJ.B. MorsO. ThomsenP.H. Age and gender differences in depressive symptomatology and comorbidity: an incident sample of psychiatrically admitted children.J. Affect. Disord.2005841859110.1016/j.jad.2004.09.003 15620389
     [Google Scholar]
  50. Ochs-RossR. WajsE. DalyE.J. ZhangY. LaneR. LimP. DrevetsW.C. SteffensD.C. SanacoraG. JamiesonC. HoughD. ManjiH. SinghJ.B. Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2, a long-term open-label phase 3 safety and efficacy study.Am. J. Geriatr. Psychiatry202110.1016/j.jagp.2021.01.123 34750057
     [Google Scholar]
  51. SnaithR.P. HamiltonM. MorleyS. HumayanA. HargreavesD. TrigwellP. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale.Br. J. Psychiatry199516719910310.1192/bjp.167.1.99 7551619
     [Google Scholar]
  52. Arrua-DuarteE. Migoya-BorjaM. BarrigónM.L. BarahonaI. Delgado-GomezD. CourtetP. ArocaF. RizviS.J. KennedyS.H. QuiltyL.C. Baca-GarcíaE. Spanish adaptation of the Dimensional Anhedonia Rating Scale (DARS).J. Affect. Disord.201924570270710.1016/j.jad.2018.11.040 30447569
     [Google Scholar]
  53. McIntyreR.S. LoftH. ChristensenM.C. Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder.Neuropsychiatr. Dis. Treat.20211757558510.2147/NDT.S296451 33654400
     [Google Scholar]
  54. WeiY.B. YangJ.R. YinZ. GuoQ. LiangB.L. ZhouK.Q. Genitourinary toxicity of ketamine.Hong Kong Med. J.2013194341348 23832948
     [Google Scholar]
/content/journals/cn/10.2174/1570159X23666240923112548
Loading
Comparison of the Antianhedonic Effects of Repeated-dose Intravenous Ketamine in Older and Younger Adults with Major Depressive Episode
Curr. Neuropharmacol. 23, 232 (2025); https://doi.org/10.2174/1570159X23666240923112548
/content/journals/cn/10.2174/1570159X23666240923112548
/content/journals/cn/10.2174/1570159X23666240923112548
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): anhedonia; depression; Ketamine; major depressive disorder; older adults; younger adults

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test